TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07123454: A Modular Phase I/II Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of AZD4512 Monotherapy or in Combination With Other Anticancer Agent(s), in Part

Sponsor: AstraZeneca · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 164 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$8,325,240

Rescue Site Savings

+$5,497,800

Unlock Full NCT07123454 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07123454 Rescue Dossier →